FDA Accepts MOGENRY Application for Severe Retinitis Pigmentosa

Evidence Company disclosure · Discovery September 9, 2026 · Importance 5/5 · Direction Positive Summary FDA accepted and filed Nanoscope Therapeutics’ biologics license application for MOGENRY, or sonpiretigene isteparvovec, in retinitis pigmentosa with severe vision loss. The one-time intravitreal optogenetic therapy is intended to work…